$RVTY

RBC Capital Markets initiated coverage on Revvity Inc. with a Sector Perform rating and a $135 price target. The company's stock is currently trading at $128.67, reflecting a 4.61% year-to-date increase and a 32.99% gain over the past year. RBC's rating is based on a weighted average of valuation, EPS revisions, and visibility metrics.

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

Revvity (NYSE: RVTY) director Alexis P. Michas reported a gift of 285 shares of common stock by The Cayre and Alexis Michas Foundation Corp. to a charity. Post-transaction, the foundation holds 6,985 shares indirectly, Michas holds 63,780 shares directly, and a spouse IRA holds 500 shares indirectly. Michas disclaims beneficial ownership of the foundation-held shares except for pecuniary interest.

T. Rowe Price Investment Management, an institutional investment adviser, disclosed beneficial ownership of 18,269,089 shares of Revvity Inc common stock, or 16.4% of the class. It reported sole voting power over 17,089,376 shares and sole dispositive power over 18,269,089 shares. The T. Rowe Price Capital Appreciation Fund holds 11,237,061 shares (10.1%).

Revvity (RVTY) reported Q2 2026 pro forma revenue of $711 million, up 3% organically, and pro forma adjusted EPS of $1.41. Diagnostics revenue rose 11% organically, while Signals software declined 20% organically. Free cash flow was $184 million. Full-year organic growth guidance was raised to 4% to 5% and adjusted EPS to $5.30 to $5.40.

Revvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.

Revvity, Inc. reported Q2 2026 results, citing improving pharma and biotech spending and higher orders tied to AI-driven drug discovery. Management said Opera Phenix OptIQ demand outpaces capacity, raised full-year organic growth guidance to 4% to 5%, and expects Signals software double-digit growth in H2. It signed an agreement to divest China immunodiagnostics and targets gross leverage below 3x by year-end.

Revvity (RVTY) reported Q2 2026 adjusted EPS of $1.41, up 19.5% and above the $1.23 Zacks estimate. Revenue rose 1.3% to $729.7 million, beating $704.5 million. Pro forma revenues were $711.1 million. Diagnostics grew; Life Sciences declined. Revvity raised 2026 pro forma revenue to $2.83-$2.86B and EPS to $5.30-$5.40 and agreed to divest China Immunodiagnostics.

Revvity, Inc. (RVTY) revised higher annual guidance, increasing its fiscal 2026 outlook for pro forma adjusted earnings and related revenue expectations, according to the company. A separate report said Revvity’s Q2 bottom line fell to $51.820 million, or $0.47 per share, versus the prior year period.

Revvity (NYSE: RVTY) reported Q2 CY2026 results. Revenue rose 7.2% year on year to $729.7 million, exceeding analysts’ estimates by 3.2%. Full-year revenue guidance is $2.85 billion at the midpoint, 0.5% above estimates. Non-GAAP EPS was $1.41, 15.9% above consensus.